Education
About Us
Working with TipRanks
Follow Us
Biofrontera, Inc. (BFRI)
NASDAQ:BFRI
BFRI Stock Chart & Stats
$0.74
$0.09(8.11%)
At close: 4:00 PM EST
$0.74
$0.09(8.11%)
Day’s Range― - ―
52-Week Range$0.54 - $1.24
Previous CloseN/A
Volume12.39M
Average Volume (3M)120.49K
Market Cap
$9.60M
Enterprise Value$0.00
Total Cash (Recent Filing)$3.42M
Total Debt (Recent Filing)$4.91M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Apr 03, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding11,648,323
10 Day Avg. Volume72,915
30 Day Avg. Volume120,486
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.36
Price to Sales (P/S)0.16
P/FCF Ratio-0.58
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$6.00Price Target Upside710.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.42
Revenue Forecast (FY)$40.14M
Bulls Say, Bears Say
Bulls Say
Asset MonetizationThe transaction is positive for Biofrontera as it monetizes an asset that was not aligned with the company’s future focus, boosting the company’s cash position.
Operational EfficienciesThe company looks to gain cost savings and operational efficiencies from the favorable restructuring of its agreements with former parent Biofrontera AG.
Product Competitive AdvantageXepi is the only drug in its class approved by the FDA with activity against bacteria that are resistant to treatment with methicillin (MRSA).
Bears Say
Increased Cost Of Goods SoldAnalyst is raising COGS estimates by 15%, assuming the EU tariff rate prevails.
Revenue Shift ChallengesThe company was not anticipating any price increases, creating tougher comps for 3Q due to the lack of stocking orders, which is leading to a shift in revenue into 4Q.
Tariff UncertaintyPotential tariff and pricing uncertainty on pharmaceuticals are lessened but not eliminated following an announcement from Pfizer, as Biofrontera Inc. appears to fall under the current 15% tariff regime negotiated with the European Union.
Biofrontera News
BFRI FAQ
What was Biofrontera, Inc.’s price range in the past 12 months?
Biofrontera, Inc. lowest stock price was $0.54 and its highest was $1.24 in the past 12 months.
What is Biofrontera, Inc.’s market cap?
Biofrontera, Inc.’s market cap is $9.60M.
When is Biofrontera, Inc.’s upcoming earnings report date?
Biofrontera, Inc.’s upcoming earnings report date is Apr 03, 2026 which is in 79 days.
How were Biofrontera, Inc.’s earnings last quarter?
Biofrontera, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.58 by -$0.04.
Is Biofrontera, Inc. overvalued?
According to Wall Street analysts Biofrontera, Inc.’s price is currently Undervalued.
Does Biofrontera, Inc. pay dividends?
Biofrontera, Inc. does not currently pay dividends.
What is Biofrontera, Inc.’s EPS estimate?
Biofrontera, Inc.’s EPS estimate is 0.15.
How many shares outstanding does Biofrontera, Inc. have?
Biofrontera, Inc. has 11,648,323 shares outstanding.
What happened to Biofrontera, Inc.’s price movement after its last earnings report?
Biofrontera, Inc. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.58. Following the earnings report the stock price went down -8.53%.
Which hedge fund is a major shareholder of Biofrontera, Inc.?
Currently, no hedge funds are holding shares in BFRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biofrontera, Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
BFRI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture, with stable year-to-date revenues, strategic expansions, successful patent approval, and financial agreements being positive aspects. However, these were countered by a decline in third-quarter revenues, increased legal costs, and a higher net loss.View all BFRI earnings summariesBFRI Stock 12 Month Forecast
Average Price Target
$6.00
▲(710.81% Upside)
Technical Analysis
Ownership Overview
12.05% Insiders
0.79% Mutual Funds
19.05% Other Institutional Investors
67.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---